Is the 21-gene recurrence score a cost-effective assay in...

Expert Review of Pharmacoeconomics & Outcomes Research 2013 / 04 Vol. 13; Iss. 2

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

Lamond, Nathan WD, Skedgel, Chris, Younis, Tallal
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Language:
english
Journal:
Expert Review of Pharmacoeconomics & Outcomes Research
DOI:
10.1586/erp.13.4
Date:
April, 2013
File:
PDF, 922 KB
english, 2013
Conversion to is in progress
Conversion to is failed